BetterLife Pharma names Mahan Chehrenama chief medical officer
- BetterLife Pharma named Mahan Chehrenama as chief medical officer to lead clinical development of BETR-001.
- BETR-001 is advancing toward an IND application for migraine and other headache disorders targeted for Q1 2027.
- Chehrenama was most recently chief medical officer at Manistee Therapeutics, leading IND submission and Phase 1-2 migraine trials for MTX-101.
- Earlier roles included global development lead at Amgen on Aimovig, a CGRP-inhibitor migraine therapy.
- Chehrenama is a board-certified neurologist and headache sub-specialist with clinical practice since 1998 and more than 90 clinical trials.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BetterLife Pharma Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608190800NEWSFILECNPR____20260819_310333_1) on August 19, 2026, and is solely responsible for the information contained therein.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Trade now！
You may also like
Crypto prices
More
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now